DC4U, an immunology company developing innovative treatments for auto-immune diseases and allergies, has been awarded a €1.7m Eurostars (SiaDM) grant, together with a Leiden University Medical Center (LUMC) research group, for the joint development of an innovative treatment for Type 1 diabetes.
The new groundbreaking approach uses – paradoxically – sugars to re-educate the immune response and restore tolerance to the insulin-producing beta cells in the pancreatic islets of Langerhans. This can accelerate the development of a potential cure for Type 1 diabetes.
Professor Bart Roep, Professor of Diabetology, Immunopathology & Intervention and Director of the Dutch National Diabetes Center of Excellence at the Leiden University Medical Center, commented: “I’m thrilled that we’ve been awarded this Eurostars grant, as with this project we will be one important step further in a career-long journey to translate new understanding of the mechanisms leading to Type 1 diabetes to finding a solution for millions of patients suffering from this condition.”
